Finasteride vs PP405
FDA Approved vs Emerging
compatible Researched · 90% Completely different mechanisms of action. Finasteride blocks DHT production via 5-alpha reductase inhibition, while PP405 targets hair follicle stem cell metabolism via MPC inhibition. Combination could be synergistic by addressing both hormonal miniaturization and stem cell dormancy simultaneously.
Molecular Data
Finasteride PP405
Weight 372.54 Da ~300-400 Da (exact structure not fully published)
Half-life 6-8 hours (DHT suppression persists ~24 hours) Topical application; exact pharmacokinetics not published
Type Synthetic 4-azasteroid compound Small molecule mitochondrial pyruvate carrier (MPC) inhibitor
Key Benefits
Finasteride
01 Reduces scalp DHT by approximately 66% at 1mg daily
02 Slows or stops hair loss progression in roughly 90% of men
03 Produces visible hair regrowth in approximately 48% of men within 1-2 years
04 FDA-approved with over 25 years of clinical use and long-term safety data
05 Convenient once-daily oral dosing with no injections required
06 Well-characterized side effect profile with low incidence of adverse events
07 Can be combined with minoxidil for enhanced efficacy
PP405
01 Novel non-hormonal mechanism of action targeting hair follicle stem cell metabolism
02 Directly addresses the root cause of follicle dormancy rather than downstream hormonal effects
03 Potentially effective regardless of androgen status, broadening the treatable population
04 Topical application (0.05% gel) limits systemic exposure
05 Phase 2a results demonstrated increased hair count and thickness
06 Compatible with existing hair loss treatments (finasteride, minoxidil) for combination therapy
07 No known sexual or hormonal side effects based on available trial data
Side Effects
Finasteride
Decreased libido (reported in 1.8% of men in clinical trials vs 1.3% placebo)
Erectile dysfunction (reported in 1.3% vs 0.7% placebo)
Decreased ejaculate volume (reported in 0.8% vs 0.4% placebo)
PP405
Scalp irritation at the application site
Application site reactions (redness, dryness, itching)
Contraindications
Women who are pregnant or may become pregnant (finasteride is teratogenic and can cause abnormalities of external genitalia in a male fetus; even handling crushed tablets poses a risk)
Women who are breastfeeding
Known hypersensitivity to finasteride or any component of the formulation
Severe hepatic impairment (finasteride is metabolized by the liver)
Pediatric patients (not indicated for use in children)
Known hypersensitivity to PP405 or any component of the gel formulation
Full contraindication profile has not been established (investigational drug)
Pregnant or breastfeeding women should avoid use until safety data is available
Research Evidence
Finasteride PP405
Status FDA Approved Emerging
References 5 studies 2 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.